Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday’s Mid-Day Session
Gainers
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.
Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.
Allena Pharmaceuticals Announces Completion Of Enrollment Of Cohorts A And B Of ALLN-346 Phase 2a Study 202 In Patients With Gout And Stages 2 And 3 Chronic Kidney Disease
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class,
Why Is Ericsson Down By 9%? 22 Stocks Moving In Thursday’s Pre-Market Session
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 22.1% to $0.2050 in pre-market trading. Allena Pharmaceuticals disclosed a new meeting date and new record date for special meeting to approve reverse stock split.
Twitter Shares Surge Around 8%, Here’s 66 Biggest Movers From Yesterday
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Gainers
Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
Why These Casino Stocks Are Moving Lower, Here’s 45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study.
Tesla, Twitter And 76 Biggest Movers From Friday
Gainers
Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale.